SUMMARY {#sec1-1}
=======

The recently published TITAN trial evaluated the role of adding apalutamide in metastatic castration-sensitive prostate cancer (mCSPC). Currently, androgen deprivation therapy (ADT) + docetaxel and ADT + abiraterone are the standard treatments of mCSPC. Apalutamide (ARN509) is an irreversible nonsteroidal androgen receptor antagonist. The TITAN trial is a phase 3, randomized, double-blind, placebo-controlled trial on apalutamide + ADT versus ADT alone in mCSPC. Results of the trialhave been published in the *New England Journal of Medicine* in July 2019.\[[@ref1]\] It included CSPC patients with distant metastatic disease measured by ≥1 lesion on bone scan, with or without visceral/lymph node involvement and ECOG performance status of 0--1. A total of 1052 patients were enrolled in two Groups: Group 1 (apalutamide 240 mg plus ADT) -- *n* = 525 and Group 2 (placebo + ADT) -- *n* = 527. The overall survival (OS) at 24 months was 82.4% in the Group 1 and 73.5% in the Group 2 (33% risk reduction of death). At 2 years, the radiographic progression-free survival was 68% in Group 1 and 48% in Group 2 (52% risk reduction of radiographic progression or death). OS benefit was also consistent through all the subgroups. It also prolonged time to cytotoxic chemotherapy (61% risk reduction) and second PFS (32% risk reduction). Most common side effect was rash (27% in Group 1 and 8.5% in Group 2), and the most common adverse event of Grade 3 or higher was also rash of any type (6.3%). Hypothyroidism was seen in 6.5% of the patients in the apalutamide group.

COMMENTARY {#sec1-2}
==========

The focus of recent advances in carcinoma prostate has now shifted from the management of castrate-resistant to castrate-sensitive patients. Various trials and the median OS for mCSPC are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Summary of trials on metastatic castrate sensitive prostate cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                       Comparison                                  Median OS in months   HR                                      Grade ≥3 AEs (most common)
  --------------------------- ------------------------------------------- --------------------- --------------------------------------- -------------------------------------------
  STAMPEDE arm C\[[@ref2]\]   ADT + AA + prednisone versus ADT            OS 37% improved       HR=0.61 (0.49-0.75)                     Hypertension (5%)

  LATITUDE\[[@ref3]\]         ADT + abiraterone + prednisone versus ADT   53.3 months versus\   HR=0.66 (95% CI 0.56-0.78), *P=*0.006   Hypertension (21%) and hypokalemia (12%)
                                                                          36.5 months                                                   

  ARCHES\[[@ref4]\]           ADT + enzalutamide versus ADT                                     HR=−0.81 (0.53-1.25), *P=*0.3361        Hypertension 3.3%\
                                                                                                                                        AEs leading to withdrawal (7.2% vs. 5.2%)

  TITAN\[[@ref1]\]            ADT + apalutamide versus ADT                OS at 24 months\      HR=0.67 (95% CI 0.51-0.89)              Rash (6.3%) and hypothyroidism (6.5%)
                                                                          82.4% versus 73.5%                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS=Overall survival, HR=Hazard ratio, AA=Abiraterone acetate, ADT=Androgen deprivation therapy, CI=Confidence interval, AEs=Adverse events

In a meta-analysis that included CHAARTED, STAMPEDE arm C, and GETUG-AFU 15 trial data, ADT + docetaxel was confirmed to significantly improve the median OS (hazard ratio \[HR\] 0.77; 95% confidence interval \[CI\] 0.68--0.87) and the median failure-free survival (HR 0.64; 95% CI 0.58--0.70) compared with ADT alone. CHAARTED/STAMPEDE (arm C/E), GETUG-AFU15, and subsequent meta-analysis established ADT + docetaxel as a standard of care (SOC) for high-volume mCSPC with good performance status and LATITUDE/STAMPEDE arm G, established ADT + abiraterone acetate and prednisone as a SOC for mCSPC, regardless of the disease volume status and performance status. Therefore, ADT + docetaxel should be preferred for men with good performance status, who have high-volume disease, desire shorter total treatment time, or have concerns of prescription drug costs, while ADT + abiraterone should be considered for men regardless of disease volume, who desire to avoid possible chemotherapy toxicity, or who want to minimize facility visits for docetaxel administration. ADT + apalutamide is a new addition with similar benefit and can be added to men where abiraterone is not tolerated (due to mineralocorticoid excess) or is discontinued due to toxicity (hepatotoxicity).

Apalutamide is preferred over enzalutamide because the ARCHES trial showed that for men with liver metastasis, enzalutamide has no discernible benefit.\[[@ref5]\] Again, during the preclinical development in animal model, apalutamide as compared to enzalutamide showed a steady-state plasma concentration 2--4-fold lower for the equivalent doses, whereas inter-tumoral level was roughly equivalent, with a greater antitumor activity at a lower dose and higher tumor/plasma ratio.\[[@ref6]\] Brain (central nervous system) level of apalutamide were 4-fold lower than those observed with enzalutamide, indicating a lower risk of seizure activity.\[[@ref6]\]
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